Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2019;9(4):665-679.
doi: 10.3233/JPD-181518.

Predicting Progression in Parkinson's Disease Using Baseline and 1-Year Change Measures

Lana M Chahine  1 , Andrew Siderowf  2 , Janel Barnes  3 , Nicholas Seedorff  3 , Chelsea Caspell-Garcia  3 , Tanya Simuni  4 , Christopher S Coffey  3 , Douglas Galasko  5 , Brit Mollenhauer  6 , Vanessa Arnedo  7 , Nichole Daegele  8 , Mark Frasier  7 , Caroline Tanner  9 , Karl Kieburtz  10 , Kenneth Marek  8 ; The Parkinson’s Progression Markers Initiative
Affiliations
Multicenter Study

Predicting Progression in Parkinson's Disease Using Baseline and 1-Year Change Measures

Lana M Chahine et al. J Parkinsons Dis. 2019.

Abstract

Background: Improved prediction of Parkinson's disease (PD) progression is needed to support clinical decision-making and to accelerate research trials.

Objectives: To examine whether baseline measures and their 1-year change predict longer-term progression in early PD.

Methods: Parkinson's Progression Markers Initiative study data were used. Participants had disease duration ≤2 years, abnormal dopamine transporter (DAT) imaging, and were untreated with PD medications. Baseline and 1-year change in clinical, cerebrospinal fluid (CSF), and imaging measures were evaluated as candidate predictors of longer-term (up to 5 years) change in Movement Disorders Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) score and DAT specific binding ratios (SBR) using linear mixed-effects models.

Results: Among 413 PD participants, median follow-up was 5 years. Change in MDS-UPDRS from year-2 to last follow-up was associated with disease duration (β= 0.351; 95% CI = 0.146, 0.555), male gender (β= 3.090; 95% CI = 0.310, 5.869), and baseline (β= -0.199; 95% CI = -0.315, -0.082) and 1-year change (β= 0.540; 95% CI = 0.423, 0.658) in MDS-UPDRS; predictors in the model accounted for 17.6% of the variance in outcome. Predictors of percent change in mean SBR from year-2 to last follow-up included baseline rapid eye movement sleep behavior disorder score (β= -0.6229; 95% CI = -1.2910, 0.0452), baseline (β= 7.232; 95% CI = 2.268, 12.195) and 1-year change (β= 45.918; 95% CI = 35.994,55.843) in mean striatum SBR, and 1-year change in autonomic symptom score (β= -0.325;95% CI = -0.695, 0.045); predictors in the model accounted for 44.1% of the variance.

Conclusions: Baseline clinical, CSF, and imaging measures in early PD predicted change in MDS-UPDRS and dopamine-transporter binding, but the predictive value of the models was low. Adding the short-term change of possible predictors improved the predictive value, especially for modeling change in dopamine-transporter binding.

Keywords: Parkinson’s disease; biomarkers; disease progression; surrogate endpoint.

PubMed Disclaimer

Conflict of interest statement

None of the authors report conflicts of interest related to the research covered in this article.

References

    1. Post B, Merkus MP, de Haan RJ, Speelman JD, CARPA Study Group (2007) Prognostic factors for the progression of Parkinson’s disease: A systematic review. Mov Disord 22, 1839–1851; quiz 1988. - PubMed
    1. Reinoso G, Allen JC Jr, Au WL, Seah SH, Tay KY, Tan LC (2015) Clinical evolution of Parkinson’s disease and prognostic factors affecting motor progression: 9-year follow-up study. Eur J Neurol 22, 457–463. - PubMed
    1. Venuto CS, Potter NB, Dorsey ER, Kieburtz K (2016) A review of disease progression models of Parkinson’s disease and applications in clinical trials. Mov Disord 31, 947–956. - PMC - PubMed
    1. Simuni T, Caspell-Garcia C, Coffey C, Lasch S, Tanner C, Marek K, PPMI Investigators (2016) How stable are Parkinson’s disease subtypes in de novo patients: Analysis of the PPMI cohort? Parkinsonism Relat Disord 28, 62–67. - PubMed
    1. Parkinson Progression Marker Initiative (2011) The Parkinson Progression Marker Initiative (PPMI). Prog Neurobiol 95, 629–635. - PMC - PubMed

Publication types

Substances